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ABSTRACT
Long noncoding RNAs (lncRNAs) are increasingly recognized to play major regulatory roles in development and disease. To
identify novel regulators in breast biology, we identified differentially regulated lncRNAs during mouse mammary
development. Among the highest and most differentially expressed was a transcript (Zfas1) antisense to the 59 end of the
protein-coding gene Znfx1. In vivo, Zfas1 RNA is localized within the ducts and alveoli of the mammary gland. Zfas1
intronically hosts three previously undescribed C/D box snoRNAs (SNORDs): Snord12, Snord12b, and Snord12c. In contrast
to the general assumption that noncoding SNORD-host transcripts function only as vehicles to generate snoRNAs, knockdown
of Zfas1 in a mammary epithelial cell line resulted in increased cellular proliferation and differentiation, while not
substantially altering the levels of the SNORDs. In support of an independent function, we also found that Zfas1 is extremely
stable, with a half-life >16 h. Expression analysis of the SNORDs revealed these were expressed at different levels, likely
a result of distinct structures conferring differential stability. While there is relatively low primary sequence conservation
between Zfas1 and its syntenic human ortholog ZFAS1, their predicted secondary structures have similar features. Like Zfas1,
ZFAS1 is highly expressed in the mammary gland and is down-regulated in breast tumors compared to normal tissue. We
propose a functional role for Zfas1/ ZFAS1 in the regulation of alveolar development and epithelial cell differentiation in the
mammary gland, which, together with its dysregulation in human breast cancer, suggests ZFAS1 as a putative tumor suppressor
gene.
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INTRODUCTION
Recent high-throughput studies of gene expression have
revealed there is far more genomic transcription than
previously anticipated, with the majority of the genome
being transcribed into non-protein coding RNAs (ncRNAs)
(Kapranov et al. 2002; Carninci et al. 2005; Birney et al.
2007). Although the functional significance of various
classes of small ncRNAs is becoming increasingly well-
established, the functionality of the tens of thousands of
long ncRNAs remains controversial (Babak et al. 2005;
Brosius 2005; Struhl 2007), and their functions remain
largely unknown. Large-scale studies of long ncRNAs
(lncRNAs) have shown that many are dynamically regu-
lated during differentiation and exhibit cell- and tissue-
specific expression patterns (Ravasi et al. 2006; Kapranov
et al. 2007a, 2007b; Mercer et al. 2008). Together with the
finding that lncRNA sequences, splice sites, and promoters
are subject to selection (Ponjavic et al. 2007), these ob-
servations present a compelling case that lncRNAs are
generally functional. However, given the diverse nature of
these transcripts, which have various genomic contexts
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(intergenic, overlapping, intronic, or antisense to protein-
coding mRNAs), widely different lengths (ranging from
z100 to z100,000 bases), and may be spliced or unspliced,
polyadenylated or nonpolyadenylated, and nuclear or
cytoplasmically located (Dinger et al. 2009; Mercer et al.
2009), it is likely that their functions and mechanisms will
also be highly diverse. Indeed, among the increasing
number that have been functionally investigated (Amaral
and Mattick 2008; Amaral et al. 2010), lncRNAs have been
shown to function in a variety of cellular processes including
transcriptional regulation (Feng et al. 2006), splicing (Yan
et al. 2005), translation (Wang et al. 2005), and structure and
organization of cellular components (Sunwoo et al. 2009).
Furthermore, different subsets of differentially expressed
ncRNAs have been identified in embryonic stem cell dif-
ferentiation (Dinger et al. 2008a), T-cell differentiation
(Pang et al. 2009), oligodendrogenesis (Mercer et al. 2010),
and keratinocyte differentiation (Mazar et al. 2010), suggest-
ing that any given developmental system will employ its own
distinct repertoire of lncRNAs.
Although lncRNAs are difficult to classify (Mercer et al.
2009), one definable subgroup comprises host genes for
small nucleolar RNAs (snoRNAs). SnoRNAs are a function-
ally diverse group of 60–150-nt trans-acting ncRNAs that
function as guides for the 29-O-ribose methylation or
pseudouridinylation of ribosomal and spliceosomal RNAs.
In vertebrates, most snoRNAs are intron-encoded, and their
processing typically involves splicing followed by exonucleo-
lytic trimming of the 59 and 39 ends. Although some
snoRNA host genes encode proteins, which are primarily
involved in the translational apparatus (Dieci et al. 2009),
many are spliced, polyadenylated lncRNAs, which are
considered to serve solely as a vehicle for snoRNA production
(Pelczar and Filipowicz 1998). Structurally, snoRNAs are
categorized as C/D-box snoRNAs (SNORDs) and H/ACA-
box snoRNAs (SNORAs). Both SNORDs and SNORAs are
dysregulated in various types of cancer and have been
implicated in the development and progression of human
malignancy (Dong et al. 2009; Mourtada-Maarabouni et al.
2009).
The mammary gland is one of the few organs that
undergoes cycles of development and regression throughout
adult life, with the full development of the gland proceeding
in delineated phases: embryonic, pubertal, pregnancy, lacta-
tion, and involution (Hennighausen and Robinson 2001).
Lactational development occurs with distinct morphological
and molecular changes of the epithelial cells and allows for
the production and secretion of milk. The secretory alveolar
cells represent the final cellular state of the differentiation
processes within the mammary gland (Hennighausen and
Robinson 1998). These differentiation steps taking place
during pregnancy and lactation are defined and character-
ized by the sequential activation of genes encoding the milk
proteins WDNM1, b-casein, whey acidic protein (WAP)
and a-lactalbumin in mouse (Robinson et al. 1995).
Further understanding the cellular pathways inherent to
normal mammary growth and development is a vital pre-
cursor to elucidating the mechanisms that lead to malig-
nant transformation in mammary epithelium. Therefore, to
gain a better understanding of the molecular mechanisms
that underlie development of the mammary gland and po-
tentially breast cancer and to investigate the role of ncRNA
in these processes, we performed microarray analyses and
identified 97 lncRNAs that were differentially expressed in
primary mammary epithelial cells of pregnant, lactating,
and involuting mice.
One of the identified transcripts, Zfas1, exhibited an
z10-fold decrease in RNA level between pregnancy and
lactation. The Zfas1 locus is host to three C/D-box
snoRNAs, and its transcription initiates from the antisense
strand near the 59 end of the protein-coding gene Znfx1.
We determined the expression patterns of Zfas1 and Znfx1
during mouse mammary gland development and mam-
mary epithelial cell differentiation. In contrast to previous
assumptions that noncoding snoRNA host transcripts
occurred only as vehicles to generate snoRNAs, we found
that knockdown of Zfas1 by RNA interference in a mam-
mary epithelial cell line resulted in an increase in markers
of proliferation and differentiation, despite snoRNA levels
remaining relatively constant. Furthermore, we show that
the three snoRNAs do not occur in equimolar ratios but
rather that their relative levels can vary drastically in dif-
ferent conditions, suggesting their stability is tightly regu-
lated. Given the differential expression of Zfas1 during
mammary development, we compared the expression of its
human ortholog, ZFAS1, in a panel of matched normal and
invasive ductal carcinoma tumor tissue and found ZFAS1
is down-regulated in the tumor tissue. In summary, we
propose a functional role for Zfas1 in the regulation of the
intracellular pathway affecting proliferation and milk pro-
duction in the mammary gland, which, together with its
dysregulation in human breast cancer, suggests ZFAS1 as a
possible tumor suppressor gene.
RESULTS
Identification of long ncRNAs that are dynamically
regulated in the mouse mammary gland
To identify lncRNAs (>200 nt) involved in mammary gland
development, we interrogated custom-designed microarrays
with RNA extracted from primary epithelial cells isolated
from mouse mammary glands at three distinct stages: 15-d
pregnant, 7-d lactating, and 2-d involuting. The microarray
contained probes that uniquely profile 8946 high-confidence
long ncRNAs and 29,968 mRNAs (includes alternative iso-
forms) in mouse. Analysis of these data showed significant
differential expression (B-statistic > 3; fold change > 4) of
388 mRNAs and 97 lncRNAs in developing mammary glands
(Supplemental Fig. S1; Supplemental Table S1).
Characterization of SNORD-host RNA Zfas1
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To validate our experimental model of the developing
mammary gland, we first examined the differentially
expressed coding mRNAs. The list of differentially expressed
genes (Supplemental Table S1) agreed with previously
reported data on mouse mammary development (Master
et al. 2002) and was generally consistent with expectations of
the developmental transitions under investigation (Metcalfe
et al. 1999), including dynamic regulation of mRNAs with
roles in cell proliferation, milk production, and apoptosis,
such as Bcl2- and casein-family genes. Gene ontology (GO)
analysis of differentially expressed mRNAs by Babelomics
(Al-Shahrour et al. 2006) showed enrichment in genes
associated with regulation of cell growth and size and
response to hormone stimulus (Supplemental Fig. S2). Based
on these observations, we anticipated that the differentially
expressed lncRNAs should be similarly relevant to the
biological processes underlying mammary development. In-
deed, among the differentially expressed lncRNAs, we
identified known lncRNAs, such as Dio3os, which has
previously been associated with decreased proliferation and
increased differentiation of precursor cells to mature adipo-
cytes, analogous to the transition from pregnancy to
lactation during mammary gland development (Hernandez
et al. 2007).
Zfas1 is a highly expressed, spliced lncRNA that
is regulated during mammary gland development
To identify lncRNAs for subsequent experimental exami-
nation, we ranked the list of significantly differentially
expressed lncRNAs by fold change and absolute expression
level. Next, on the basis that many lncRNAs originate from
complex transcriptional loci (Engstrom et al. 2006) in
which they may have a functional relationship with the
nearby protein-coding genes, we further refined our list of
lncRNAs by examining their genomic context. Using our
previously described classifications of lncRNA loci (Dinger
et al. 2009), we identified 15 cis-antisense, 3 nearby
antisense, 37 intronic, and 42 intergenic transcripts (Sup-
plemental Table S1). Because we were interested in
lncRNAs that may impact on human mammary develop-
ment, we further refined our list of candidates by consid-
ering only those for which there was transcriptional evi-
dence at the syntenic genomic position in human. In total,
19 of the 97 transcripts had human transcripts that arose
from syntenic locations.
Taken together, our criteria highlighted a previously
uncharacterized lncRNA, which had been annotated in
RefSeq as 1500012F01Rik (GenBank ID AK005231). Tran-
scription of this spliced lncRNA initiates from the nearby
antisense strand of the Znfx1 (zinc finger NFX-1-type
containing) promoter region (Fig. 1A; Supplemental Fig.
S3), which led to our naming of it as Zfas1 (zinc finger
antisense). As Zfas1 is not transcribed from an ultra-
conserved region (Bejerano et al. 2004) and is located close
to a protein-coding gene, it does not belong to the existing
lncRNA subclasses of T-UCRs (transcribed ultraconserved
RNAs) (Calin et al. 2007) or lincRNAs (long intergenic
noncoding RNAs) (Guttman et al. 2009). From our list of
differentially expressed lncRNAs, Zfas1 was the second
most highly expressed (A-value z10) and had the second
largest fold change (34-fold down-regulated from pregnant
to lactating) (Supplemental Table S1; Supplemental Fig.
S4). In human, the ZNFX1 locus also features an equiva-
lently positioned spliced noncoding transcript, which is
annotated in RefSeq Genes as NCRNA00275, a feature not
shared by the other highly differentially expressed tran-
scripts. Another interesting feature of this transcript is that
it hosts three snoRNA genes, Snord12, Snord12b, and
Snord12c, within sequential introns (Fig. 1A; Supplemental
Fig. S3; Supplemental Table S2). The combination of these
characteristics led us to pursue Zfas1 for further character-
ization in mammary development.
Although our ncRNA annotation program had indicated
that Zfas1 was noncoding, we noted that the sequence did
contain a 79-amino acid open reading frame (ORF). Using
BLASTP, we confirmed that this protein sequence was not
conserved among mammals and did not contain any
known protein motif. Moreover, the start and stop codons
were not conserved in the human ortholog of Zfas1, and
there was no evidence of any consensus ribosomal binding
sequences. Analysis by the CRITICA algorithm (Badger and
Olsen 1999) also indicated that the codon usage frequency
of this ORF was inconsistent with other mouse genes.
Querying PRIDE, a database of peptide sequences deduced
from proteomic analyses (Vizcaino et al. 2009), showed no
peptides have been identified that correspond to the Zfas1
ORF. Together, these observations led us to conclude that
the transcript was unlikely to encode a protein.
Zfas1 expression is differentially regulated to Znfx1
As shown in Figure 1A, Zfas1 and Znfx1 are closely
positioned in a head-to-head orientation and potentially
share a bidirectional promoter. This raises the possibility
that these genes may be coordinately regulated (Trinklein
et al. 2004; Engstrom et al. 2006; Dinger et al. 2008a;
Mercer et al. 2008). To investigate whether Zfas1 and Znfx1
are coregulated, we examined their expression profiles at
different stages of mammary gland development by quan-
titative real time PCR (qPCR). Figure 1B illustrates the
expression of these two genes relative to Tubulin delta 1
(Tubd1), a result in agreement with the microarray data
(Supplemental Fig. S4). Although Zfas1 was significantly
down-regulated (ninefold) between pregnancy and lacta-
tion and significantly up-regulated between lactation and
involution (fourfold), Znfx1 did not change appreciably
during these transitions. This, together with the finding
that the ratio of Zfas1 to Znfx1 varies from 63:1 (in
pregnancy) to 6:1 (in lactation) in different developmental
Askarian-Amiri et al.
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stages of the mammary gland, suggests that the transcripts
are independently regulated.
EST evidence from GenBank showed that Znfx1 and
Zfas1 were expressed in many other tissues outside of the
mammary gland, including kidney, brain, pancreatic bud,
thymus, eye, heart, and embryo. To obtain a more com-
prehensive profile of the relative expression levels of Znfx1
and Zfas1 in mouse, we performed qPCR on a diverse range
of tissues. Figure 1C shows the expression of Znfx1 is
significantly lower than Zfas1 in each of the tissues ex-
amined (except testis). Although the expression profiles
of Zfas1 and Znfx1 were positively correlated (Pearson
co-efficient, R = 0.77), the ratios of Zfas1 to Znfx1 varied
considerably, ranging from 1:2.6 in testis to 7.4:1 in
mammary gland (Supplemental Fig. S5). The data shows
that the highest level of expression of Zfas1 occurs in the
lung followed by mammary gland and, in contrast, is
almost undetectable in testis. Interestingly, the lung and
FIGURE 1. Relationship and expression of Znfx1 and its associated ncRNA Zfas1. (A) Genomic context of Znfx1 and its associated ncRNA. The
enlarged Zfas1 indicates the location of three snoRNAs derived from this gene. The high degree of conservation of these regions across
mammalian species is indicated. (B) Relative expression of Znfx1 (left) and Zfas1 (right) in mammary epithelial cells during different
developmental stages of mammary gland development to Tubulin delta 1 (Tubd1). Expression levels of three biological replicates for each stage
were measured in triplicate by qPCR. (C) Relative expression profile of Znfx1 and Zfas1 to Tubd1 in different tissues by qPCR. Technical replicates
were performed in triplicate for each sample. (D) Decay curve of Znfx1 and Zfas1 in N2A cells. Transcription was blocked by treatment with
actinomycin D, and expression levels of three biological replicates were detected by qPCR. Error bars in B, C, and D are the standard error of the
mean (SEM). (E) Northern blot analysis of Znfx1 and Zfas1 on RNA derived from total, cytoplasmic, and nuclear fractions of HC11 cells. Arrows
indicate size of transcript for each gene.
Characterization of SNORD-host RNA Zfas1
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mammary gland both have biologically similar alveolar
structures, raising the possibility that Zfas1 may play a role
in alveolar morphogenesis.
In addition to the various tissues, we also examined the
relative expression of Zfas1 and Znfx1 in the murine
mammary epithelial cell line HC11 during an 8-d in vitro
assay. After an initial proliferative phase in the presence of
epidermal growth factor (day 2), addition of lactogenic
hormones to the HC11 cells at day 4 stimulates lactogenic
differentiation in the formation of dome-like structures and
the expression of milk proteins by day 8. As well as again
showing discordant expression between Zfas1 and Znfx1,
the results show that Zfas1 is both highly expressed in HC11
cells and is down-regulated upon differentiation (Fig. 1C;
Supplemental Fig. S5). This is consistent with our observa-
tion of the differential expression of Zfas1 in the mammary
gland and suggests that HC11 cells serve as a meaningful
experimental model to explore Zfas1 function.
Given the overlapping promoter regions of Znfx1 and
Zfas1, the highly discordant expression of these transcripts
is surprising. One explanation for this observation is that
Zfas1 is more stable than Znfx1, resulting in higher steady-
state levels. To examine this hypothesis, we treated N2A
cells with the general transcription inhibitor actinomycin
D and quantified the expression levels after 0.5, 2, 4, 8, and
16 h (Fig. 1D). We calculated that Znfx1 had a mean half-
life of 50 min (95% confidence interval; 41–65 min). In
contrast, Zfas1 levels did not decline significantly after 16 h
(relative to GAPDH), confirming that this transcript is
indeed highly stable.
As a number of previously character-
ized lncRNAs have been shown to act
in the nucleus (Wilusz et al. 2009), we
performed Northern blot analysis on
total, nuclear, and cytoplasmic RNA
derived from HC11 cells using probes
targeting Zfas1 and Znfx1 (Fig. 1E). The
Northern hybridization for Zfas1 iden-
tified a single strong band of 0.5 kb,
which is consistent with the length
of the full-length cDNA clones of
Zfas1. The Northern hybridizations
revealed that Zfas1 was expressed in
both cytoplasmic and nuclear fractions,
while Znfx1 was highly enriched in the
nucleus.
Zfas1 is expressed in the epithelial
cells of the duct and alveoli
of the mammary gland
To further analyze Zfas1 expression, we
performed section in situ hybridization
(ISH) on mammary glands dissected
from 15-d pregnant mice. DIG-labeled
in vitro transcribed Zfas1 RNA was used to detect expres-
sion in section paraffin-embedded pregnant mammary
gland. The staining revealed enrichment of Zfas1 expression
in the epithelial cells of the ducts and alveoli of the preg-
nant mammary gland (Fig. 2) relative to the background.
Together with the high expression of Zfas1 observed in
mammary gland and lung generally, this result is consis-
tent with the notion that Zfas1 is involved in alveolar
development.
Knockdown of Zfas1 results in an increase in markers
of cell proliferation
In light of the observation that Zfas1 expression was in-
creased in the mammary gland during pregnancy when the
cells are most proliferative, we hypothesized that Zfas1 may
have a role in cell proliferation. To investigate the effect of
Zfas1 on cell proliferation, we knocked down its expression
in exponentially growing HC11 cells using several small
interfering RNAs (siRNAs) specific to Zfas1. Using qPCR to
measure the relative expression levels of Zfas1, we observed
a reduction in expression of Zfas1 relative to a scrambled
siRNA-transfected control of at least 80%, which was
maintained for up to 4 d in the Zfas1-specific siRNA-
treated cells (Fig. 3A; Supplemental Fig. S6). We also
assayed Znfx1 expression to see if attenuation of Zfas1
expression had an effect on its protein-coding partner. As
seen in Figure 3A, a similar but slightly offset change in
expression was apparent for Znfx1 over the same period
of analysis.
FIGURE 2. ISH mammary gland sections from pregnant mice. Panels illustrate mammary
gland sections hybridized with no probe (top; negative control), Zfas1 antisense probe
(middle), and Zfas1 sense probe (bottom; negative control). Images in dotted boxed areas
increase in magnification from left to right. The arrows show ductal and alveolar structure and
the expression of Zfas1 within these structures. Scale bars in each panel are indicated. The
genomic context of the ISH probe is shown in Supplemental Fig. S3.
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Cell proliferation rates were determined by quantifying
incorporation of BrdU into DNA 48 h after cells were
transfected by siRNA (Fig. 3B). We found that the Zfas1-
knockdown cells displayed a higher rate of proliferation
relative to the scrambled siRNA-transfected control. To
further validate this effect, we also measured proliferation
rates in Zfas1 knockdown and control cells using an MTT
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide, a tetrazol] assay (Mosmann 1983) to measure meta-
bolic activity over a 4-h period. Consistent with the BrdU
incorporation assay, cells transfected with siRNAs targeting
Zfas1 showed increased proliferation
(Fig. 3C). Together, these results suggest
that Zfas1 may play a role in regulating
cell proliferation.
Knockdown of Zfas1 induces
b-casein expression and epithelial
dome formation
To explore the hypothesis that Zfas1 has
a regulatory role in alveolar development
in the mammary gland, we examined the
effect of knocking down Zfas1 during
a dome formation assay. Formation of
domes in cell culture, which can be
induced in HC11 cells by addition of
o-prolactin and dexamethasone, is con-
sidered to be a model for mammary epi-
thelial cell differentiation (Zucchi et al.
2002). Relative to a scrambled siRNA
control, HC11 cells that had been trans-
fected with a Zfas1-targeted siRNA
showed a marked increase in the number
of domes formed following induction
(Fig. 3D). O-prolactin- and dexametha-
sone-induced HC11 differentiation is
also characterized by increased expres-
sion of b-casein. To further characterize
the role of Zfas1 in this developmen-
tal model, we determined the response
to Zfas1-knockdown in comparison to a
scrambled siRNA-knockdown by mea-
suring the expression level of Csn2 (b-ca-
sein) in differentiated (day 8) relative to
undifferentiated (day 2) cells. We found
that in Zfas1 knockdown cells, the ex-
pression of Csn2 increased over 40-fold
in differentiated cells relative to undiffer-
entiated cells, whereas it increased just
twofold in cells transfected with the
control siRNA (Fig. 3E). Together, these
results suggest that Zfas1 may play a role
in regulating HC11 differentiation.
SnoRNAs derived from Zfas1 are differentially
expressed
Zfas1 is predicted to host three C/D box-containing ho-
mologous snoRNA genes, Snord12, Snord12b, and Snord12c,
in consecutive introns (Fig. 1A). Intronic snoRNAs have
been identified in all eukaryotic genomes and are frequently
distributed in noncoding genes in this manner, with one
snoRNA per consecutive intron (Huang et al. 2005). C/D
box snoRNAs primarily guide the site-specific methylation
of other RNAs, mainly ribosomal RNAs. Snord12 and
FIGURE 3. Effect of Zfas1 knockdown by RNA interference. (A) The expression level,
normalized to Tubd1, of Znfx1 and Zfas1 genes in HC11 cells transfected with Zfas1 siRNA
relative to the respective expression of each gene in HC11 cells transfected with scrambled
siRNA measured by qPCR 1–5 d after siRNA transfection. Technical replicates were performed
in triplicate for each time point, with error bars indicating SEM. (B) Proliferation rates based
on level of BrdU incorporation measured 48 h after cells were transfected with Zfas1 versus
scrambled siRNA. Six technical replicates were performed with error bars indicating SEM. (C)
MTT assay measuring the metabolic rate of HC11 cells transfected with Zfas1 versus scrambled
siRNA. Six technical replicates were performed with error bars indicating SEM. (D) Effect of
Zfas1 knockdown compared to the scrambled siRNA control on dome formation in
differentiated HC11 cells measured on day 8. (E) Quantitative PCR, relative to Tubd1, of
b-casein (Csn2) levels in differentiated (day 8) cells relative to undifferentiated (day 2) in
HC11 cells transfected with Zfas1 or scrambled siRNA. The results in D and E represent data
from three experiments, each with three technical replicates, with error bars indicating the
SEM of the three experiments.
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Snord12b (previously referred to as MBII-99 and MBII-
99B) are predicted to modify Gm3868 and Gm3878,
respectively, in 28S rRNA (Huttenhofer et al. 2001; Yang
et al. 2006). Snord12c (previously referred to as Snord106 or
U106) contains antisense elements that match the G1536
and U1602 segments in 18S rRNA. However, as there is no
evidence for methylation at these sites, Snord12c may
function solely as an RNA chaperone or target chemical
modifications in a nonribosomal transcript. The predicted
size for Snord12, Snord12b, and Snord12c are z85, z87,
and z93 nucleotides, respectively.
As the three Zfas1 snoRNAs had not previously been
examined in mouse (Snord12b and Snord12c are unanno-
tated in RefSeq and UCSC Known Genes), we designed
primers to detect the expression of these SNORDs. Using
cDNA prepared from mouse mammary epithelial cells, we
were able to confirm the existence of all three snoRNAs.
Next, we aimed to determine the relative expression levels
of Snord12, Snord12b, and Snord12c in mammary epithelial
tissue from pregnant, lactating, and involuting mice. Using
qPCR (TaqMan), each of the snoRNAs was found to be
most highly expressed during pregnancy (Fig. 4A), consis-
tent with the higher expression of the host transcript Zfas1
in pregnancy. However, in contrast to Zfas1, which shows
increased expression in involuting relative to lactating
mammary epithelial cells, the SNORDs are expressed at
similar levels at these developmental stages. Surprisingly,
given that the three snoRNAs are derived from the same
host transcript, Snord12b was expressed at up to 171-fold
and 72-fold greater levels than Snord12c and Snord12,
respectively. To examine whether the expression trends of
Snord12, Snord12b, and Snord12c were similar in differen-
tiating HC11 cells, we used qPCR to examine their ex-
pression levels in 2-, 4-, and 8-d differentiated HC11 cells
(Fig. 4B). Although we found Snord12b was more highly
expressed than Snord12 and Snord12c, the difference in
expression was much less dramatic (approximately eight-
fold and approximately fivefold for Snord12c and Snord12,
respectively). Similar to the expression trend of Zfas1,
the snoRNAs were consistently most highly expressed in
FIGURE 4. Expression of snoRNAs that are intronic to Zfas1. (A) Relative expression (from left to right) of Snord12, Snord12b, and Snord12c to
Snord68 during different mammary gland developmental stages. Expression levels of three biological replicates for each stage were measured in
triplicate by qPCR. (B) Expression levels (from left to right) of Snord12, Snord12b, and Snord12c during HC11 cell differentiation relative to
Snord68. Expression levels of two biological replicates for each stage were measured in triplicate by qPCR. Error bars in both A and B are SEM of
the biological replicates. (C) Decay curve of Snord12, Snord12b, and Snord12c in N2A cells. Transcription was blocked by treatment with
actinomycin D, and expression levels were detected in triplicate by qPCR. Errors are the standard error of the mean (SEM). (D) Northern blot
analysis of Snord12, Snord12b, and Snord12c (see Fig. 1A and Supplemental Fig. S3 for genomic positions) expression in total, cytoplasmic, and
nuclear RNA derived from undifferentiated HC11 cells. (E) Expression levels of Snord12, Snord12b, and Snord12c, normalized to Snord68, in
undifferentiated (day 2) HC11 cells transfected with Zfas1 siRNA relative to expression levels of each normalized gene in HC11 cells transfected
with scrambled siRNA. Technical replicates were performed in triplicate, with error bars indicating SEM.
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undifferentiated HC11 cells (day 2) and decreased signif-
icantly in differentiated (day 4 and 8) cells.
One explanation for the highly differential molar ratios
of Snord12, Snord12b, and Snord12c is that they have
different stabilities. Using the same approach as described
above to determine the stability of Znfx1 and Zfas1, we
blocked transcription and determined the expression levels
of the three SNORDs. We found that Snord12 and Snord12c
levels decreased rapidly (with half-lives of 43 min and 37
min, respectively) following transcriptional inhibition,
whereas Snord12b levels did not change appreciably even
after 16 h (Fig. 4C). Although these snoRNAs are similar in
sequenc and are accordingly considered to belong to the
same family, we hypothesized that they may fold into
different structures. To examine this hypothesis, we used
MFOLD to predict the secondary structures of the three
snoRNAs (see Supplementary Methods). Interestingly,
Snord12b, which had exhibited much higher expression
levels than Snord12 and Snord12c, folded into a distinct
structure with an additional short hairpin in relation to
Snord12 and Snord12c, which folded into the traditional
secondary structure of C/D box snoRNAs (Supplemental
Fig. S3).
As the Zfas1 transcript was detected in both nuclear and
cytoplasmic fractions of HC11 cells, we examined the
cellular localization of the snoRNAs. We prepared total
RNA from HC11 cells and subsequently fractionated the
cells into nuclear and cytoplasmic portions. Consistent with
the qPCR data, Northern blot analysis indicated a high level
of expression for all three Zfas1-derived snoRNAs, but
unlike Zfas1, SNORD expression was specific to the nuclear
fraction of these cells (Fig. 4D). The Northern analysis
showed a single band of the predicted size for each
snoRNA. The absence of smaller fragments in the Northern
blot as well as examination of small RNA deep sequencing
data (Taft et al. 2009) suggests that, unlike previous reports
of other snoRNAs (Ender et al. 2008; Taft et al. 2009),
Snord12, Snord12b, and Snord12c are not processed into
smaller RNAs.
Although the siRNA-mediated knockdown of Zfas1
should not affect the expression of Snord12, Snord12b,
and Snord12c, which we would expect to be spliced out of
the Zfas1 prior to siRNA-directed breakdown of the host
transcript, we nevertheless wished to confirm that the phe-
notypic changes observed during Zfas1-knockdown were
not a direct consequence of reduced SNORD expression.
Using qPCR, we found that there are only minor differ-
ences in the expression of Snord12, Snord12b, and Snord12c
in the Zfas1-knockdown compared to the scrambled siRNA
control (Fig. 4E). These small changes in expression, rel-
ative to the z80% knockdown of the host transcript,
suggest that the phenotypic changes observed following
Zfas1 knockdown are a consequence of the host transcript
and that the mature form of Zfas1 functions intrinsically as
an RNA.
Human ZFAS1 transcript exists and undergoes
regulated alternative splicing
The human ortholog of Zfas1, ZFAS1, is located on chro-
mosome 20. In terms of the relative position of its
transcription start site to ZNFX1 and the presence of
intronic snoRNA genes (Fig. 5A), the ZFAS1 locus is similar
to that in mouse. ZFAS1 is alternatively spliced with cDNA
evidence indicating the presence of at least five different
isoforms. Although the snoRNA genes (SNORD12,
SNORD12B, and SNORD12C) are highly conserved between
mouse and human (81.3%, 68.9%, and 71%, respectively),
a comparison of the exonic regions of the most prevalent
isoforms of ZFAS1 (isoforms 1-4 in Figure 5A; C20orf1999
uc002xuj.2, uc002xul.3, uc002xum.3, uc002xuo.2) with its
mouse ortholog (NM_001081005.1) shows an average of
only 43% identity. However, comparison of the secondary
structure predictions of the mature Zfas1 and ZFAS1
transcripts revealed several highly structured regions of the
transcripts were very similar despite lacking sequence iden-
tity (Supplemental Fig. S7).
To obtain an overview of ZNFX1 and ZFAS1 expression,
we performed qPCR across a panel of 20 human tissues and
the breast cancer cell lines MCF7, BT474, and T47D
(Supplemental Figs. S8, S9). Similar to the mouse tissue
data, the ratios of ZFAS1 to ZNFX1 varied across tissues
(from 2:1 in testis to 12:1 in mammary tissue). However,
overall there was a positive correlation (Pearson’s correla-
tion, R2 = 0.797, n = 20) between the expression profiles of
ZNFX1 and ZFAS1 across the tissue samples (Supplemental
Fig. S8). Analysis of publicly available transcriptomic deep
sequencing data in normal human breast tissue and
mammary epithelium (Wang et al. 2008) mirrored our
expression analysis in mouse, showing that ZFAS1 is very
highly expressed in mammary tissue (in the top 2%–5% of
all genes) (Fig. 5B).
The deep sequencing data recapitulated the presence of
at least three different isoforms of ZFAS1. Furthermore we
were able to detect ZFAS1 isoforms in RNA isolated from
MCF7, BT474, and T47D by using PCR primers designed
to common exons (Supplemental Fig. S9). To determine
whether different isoforms were alternatively regulated in
different tissue types, we examined the relative proportions of
the isoforms in the RNA deep sequencing libraries. Although
the longer isoforms were predominant in each tissue type
(ranging from z55% to z85% of the three distinguishable
groups), the relative proportions of the isoform groups
differed between tissue types, suggesting regulation of the
alternative splicing (Fig. 5C; Supplemental Fig. S9).
Human ZFAS1 levels are reduced in ductal carcinoma
relative to normal breast tissue
Given the role of Zfas1 in proliferation, we hypothesized
that decreased ZFAS1 expression may be a marker for
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breast cancer and, moreover, that ZFAS1 may be a tumor
suppressor gene. To investigate this hypothesis, we exam-
ined ZFAS1 expression in total RNA isolated from the
epithelial cells isolated by micro-dissection from frozen
sections of normal breast and invasive ductal carcinoma
(IDC) tissue (five paired and seven unpaired samples). The
result shows ZFAS1 expression is decreased (2.0-fold, p =
0.08, paired; 2.7-fold, p = 0.09, unpaired) in ductal car-
cinoma relative to normal epithelial cells (Fig. 5D; Supple-
mental Fig. S10). Taken together with the effects of Zfas1
knockdown on mammary epithelial cell proliferation and
differentiation, our results suggest ZFAS1 as a novel human
tumor suppressor gene in breast cancer and that its
dysregulation may be useful as a marker for breast cancer.
DISCUSSION
Although the importance of lncRNAs in cell function is
now becoming firmly established (Mercer et al. 2009), only
a relatively small number have been shown to be involved
in cancer (Huarte and Rinn 2010). In light of the potential
value of lncRNAs as biomarkers and therapeutic targets
(Huarte and Rinn 2010), as well as to further our un-
derstanding of the molecular mechanisms underlying cancer
formation and development, we sought to identify lncRNAs
involved in breast cancer. Under the hypothesis that
lncRNAs involved in mammary development may be dysreg-
ulated in breast cancer, we examined the expression of 8946
lncRNAs at different stages of mouse mammary gland
development and found a total of 97 that showed significant
dynamic changes. We ranked the candidates on the basis of
overall expression level, fold change, and conservation in
humans. As a result, we selected the lncRNA Zfas1, which is
positioned on the antisense strand at the 59 end of the Znfx1
protein-coding gene and is host to three C/D box snoRNAs,
for further functional examination.
Knockdown of Zfas1 in mouse mammary epithelial
cells resulted in a significant increase in proliferation and
FIGURE 5. Expression analysis of human ZFAS1. (A) Genomic context of human ZNFX1 and ZFAS1. The 59 ends of ZNFX1 and ZFAS1 are
oriented head-to-head on opposite strands. The zoomed-in regions show five different ZFAS1 isoforms that are represented by ESTs. The
positions of the intronically-derived snoRNAs—SNORD12, SNORD12B, and SNORD12C—are also shown with the degree of conservation across
mammalian species indicated. (B) Comparative expression levels (tpm) of ZNFX1 and ZFAS1 based on RNA deep sequencing of human breast
tissue and mammary epithelium. (C) Relative abundance of alternate isoforms of ZFAS1 in various human tissues and cell lines based on exon-
exon junction spanning deep sequence tags. The number on top of each bar represents the number of informative tags. (D) Relative expression
level of ZNFX1 and ZFAS1 to GAPDH in the five paired normal and invasive ductal carcinoma (IDC) samples detected by qPCR with technical
replicates performed in triplicate. Error bars indicate SEM of the biological replicates.
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metabolic activity. Examination of the expression of the
intronically hosted SNORDs following knockdown showed
that their expression was only minimally altered, suggesting
that the processed Zfas1 transcript is itself functional. The
high level of proliferation and low level of Zfas1 expression
is analogous to our observations in human mammary
tissues, where we observe a substantially decreased level
of ZFAS1 in highly proliferative invasive ductal carcinoma
cells compared to normal breast tissue. Collectively, these
observations led us to propose ZFAS1 as a putative tumor
suppressor gene.
The head to head arrangement between Zfas1 and the
oppositely transcribed protein-coding gene Znfx1 occurs
frequently in mammalian genomes (Trinklein et al. 2004;
Engstrom et al. 2006). Znfx1 and Zfas1 share a CpG island,
the methylation of which would be expected to similarly
affect the expression of these transcripts. Although in some
cases such bidirectional genes show concordant expression
profiles, consistent with the notion of shared regulatory
elements, others, as described below for Znfx1 and Zfas1,
share more complex expression relationships (Dinger et al.
2008a; Mercer et al. 2008). In both mouse and human, the
expression patterns of Znfx1 and Zfas1 were similar over a
panel of tissues, with the exception of testis and mammary
gland. In both species, relative to Znfx1, Zfas1 was con-
siderably down-regulated in testis and up-regulated in
mammary gland. The uncoupling of Znfx1 and Zfas1 ex-
pression was also evident both in the developing mammary
gland, where Znfx1 remains relatively constant while Zfas1
undergoes significant dynamic changes, and during differ-
entiation of the mouse mammary epithelial cell line HC11,
where there was an inverse relationship in the expression of
Zfas1 and Znfx1. Furthermore, knockdown of Zfas1 in
HC11 cells results in a concomitant relative decrease in
Znfx1 expression levels. However, as the levels of Zfas1
recovered following knockdown, there was an overcom-
pensation of Znfx1, which increased to more than twofold
that of normal cells. Together, these observations suggest
that the expression of Znfx1 and Zfas1 is likely to be inter-
twined and therefore may participate in the same regula-
tory network. However, because the expression of these
genes can be uncoupled in some conditions, it is likely that
there are at least some independent regulatory controls
underlying their expression and/or stability. Furthermore,
the specific up-regulation of Zfas1 relative to Znfx1 in
mammary gland suggests a specific role for Zfas1 in this
organ, particularly during development.
Although the Znfx1 protein has not been previously
studied, its predicted sequence contains an NFX-1 (nuclear
transcription factor X-box binding) zinc finger domain.
Despite the low homology between the NFX-1 binding
domain and the corresponding region in Znfx1, (26%
identity; 36% similarity over a 327-amino acids region),
the critical cysteine residues that characterize the domain
(Song et al. 1994) are highly conserved (36/40; 90%),
suggesting that Znfx1 may also bind DNA. Interestingly,
the human ortholog of Znfx1, ZNFX1 (previously referred
to as KIAA1404 or MAD-Cap5), is specifically up-regulated
in response to chemotherapeutic treatment in MCF7 and
ZR-75-1 human mammary gland cell lines (Troester et al.
2004) and is also up-regulated in the serum of patients
following treatment for prostate cancer (Dunphy and
McNeel 2005). One conclusion drawn from these studies
was that ZNFX1 might be involved in DNA repair. If Zfas1
indeed belongs to the same regulatory network as Znfx1,
then we can speculate that Zfas1 may also have some role
in a DNA repair pathway.
Alignment of mouse Zfas1 and human ZFAS1 reveals
only moderate sequence conservation, with the notable
exception of the snoRNA regions conserved in three
consecutive introns. This evident conservation of Snord12,
Snord12b, and Snord12c suggests the function of these
transcripts is likely to be conserved across mammals.
Interestingly, despite an apparent absence of alternative
splice variants of Zfas1, the Zfas1-derived snoRNAs are not
present in equal proportions. The highly differential ratios
of the snoRNAs suggest the degradation and/or stability of
the snoRNAs can vary considerably. Determination of the
half-lives of the snoRNAs confirmed this hypothesis,
showing that Snord12b was considerably more stable than
Snord12 and Snord12c. Structural predictions reflected this
differential stability, showing that Snord12b, the most
highly expressed of the snoRNAs, has a structure consistent
with increased stability. The differential stability/degrada-
tion of snoRNAs at the various stages of mammary
development raises the hypothesis that the target region
for these snoRNAs may be important during mammary
gland development and, consequently, that the dysregula-
tion of their expression levels may have important conse-
quences in breast cancer etiology.
The moderate sequence homology of the evolutionarily
conserved Zfas1 and ZFAS1 led us to look beyond nucleo-
tide alignment of these orthologs. A number of ncRNAs
have characteristic structures that are functional and hence
are well conserved over evolutionary timescales. Most of
the ‘‘classical’’ ncRNAs, including rRNAs, tRNAs, small
nuclear RNAs (snRNAs), snoRNAs, as well as the RNA
components of RNAse P and the signal recognition par-
ticle, show this evolutionary conservation of structure and
function (Washietl et al. 2005). Comparison of the pre-
dicted secondary structures of the human and mouse forms
of Zfas1 revealed several distinct regions that had almost
identical structures, despite sharing minimal sequence
identity over these areas. The remarkable stability of Zfas1
(half-life of >16 h), as well as the presence of conserved
structures within Zfas1, implies that the RNA has functions
beyond its role as a host for generating snoRNAs. This
notion is supported by the observed lack of effect on
snoRNA transcript levels upon siRNA-mediated Zfas1
knockdown. Thus, the phenotypic effects caused by the
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reduction of Znxf1-as indicate that, in this case, the
snoRNA host transcript is itself functional. This may also
be the case for many other noncoding host transcripts, as
has been recently shown for the Gas5 SNORD host gene
(Kino et al. 2010), as well as host transcripts for miRNA
host genes, such as H19 (Gabory et al. 2010) and BIC
(Eis et al. 2005).
In summary, we show that the mature spliced transcript
of an RNA that harbors C/D-box snoRNAs can function
independently of the snoRNAs. This RNA is highly regu-
lated in the developing mouse mammary gland, acts as
a repressor of proliferation and differentiation, and is
dysregulated in human breast cancer. Our results highlight
the importance of the largely unexplored population of
non-protein-coding genes in understanding the molecular
basis of disease and as sources of potential biomarkers and
therapeutic targets.
MATERIALS AND METHODS
Animals and mammary epithelial cells isolation
All experiments were performed with Balb/c mice, which were
maintained and handled according to Australian guidelines for
animal safety. All experiments were approved by the Animal
Research Ethics Committee of the University of Queensland. The
mice were mated and then sacrificed at day 15 of pregnancy, day 7
of lactation, and day 2 of involution. Nine mice from each stage
were sacrificed, and mammary glands were dissected. One
thoracic gland from each mouse was fixed for in situ hybridization
and remaining glands were pooled to create three pools for each
developmental stage and processed for epithelial cell purification
as described previously (Tan-Wong et al. 2008). For the adult
mouse tissue expression analysis, brain, liver, lung, kidney, spleen,
and testis were dissected from a single male mouse, the whole
mammary gland tissue was derived from a virgin female mouse,
and whole embryos were harvested from a single mouse 10.5
d post-coitum.
RNA extraction
Total cellular RNA from mammary gland epithelial cells or
cultured cells or other tissues from mouse was purified using
Trizol (Invitrogen) according to the manufacturer’s instructions.
For further detail on RNA extraction and qPCR analyses, see
Supplemental Methods.
Microarray analyses
Custom-designed microarrays (ArrayExpress accession number
A-MEXP-1958) were synthesized by NimbleGen, and experiments
performed according to the manufacturer’s instructions. The
noncoding transcripts targeted by the custom microarray were
identified using the CRITICA software, which uses a combination
of statistical and comparative parameters, such as open reading
frame (ORF) length, synonymous versus nonsynonymous base
substitution rates, and similarity to known proteins (Badger and
Olsen 1999; Frith et al. 2006). Although we cannot eliminate the
possibility that small proteins or peptides are encoded by these
transcripts (Dinger et al. 2008b), BLASTP searches of predicted
ORFs indicated they did not contain any known protein motif and
were not conserved in other species. Raw and normalized micro-
array data is available at the ArrayExpress Data Warehouse
(EMBL-EBI; ArrayExpress Accession Number E-TABM-1106).
For expression analyses, see Supplemental Methods.
In situ hybridization
In situ hybridization (ISH) was performed using digoxigenin
(DIG)-labeled complementary RNA probes. In vitro transcription
was performed according to the manufacturer’s instructions using
the Promega T7/SP6 reverse transcription kit to produce sense
(control) and antisense ISH probes. Section ISH was performed
on 5-mm sections of paraformaldehyde-paraffin-embedded 15-d
pregnant mouse mammary glands (see Supplemental Methods for
details).
Northern blot analysis
Northern blot analysis was performed as previously described
(Amaral et al. 2009). The Zfas1 probe used for Northern blot
analysis was the same antisense Zfas1 PCR product that was used
for in situ hybridization. Both the Zfas1 and Znfx1 probe (see
Supplemental Table S3 for primer sequences) were random-
labeled (GE Healthcare) according to the manufacturer’s instruc-
tions. The snoRNA probes were prepared by amplifying the
respective genes using the primers listed in Supplemental Table
S3 and were randomly labeled as above.
Cell lines
Mouse HC11 cells were cultured and induced to differentiation in
an eight-day assay as previously described (Naylor et al. 2005).
T47D, BT474, MCF7, and N2A were cultured as described
previously (Soule et al. 1973; Keydar et al. 1979; Lasfargues
et al. 1979; Georgopoulou et al. 2006).
RNA stability assay
N2A cells were grown to z50% confluence, before addition of 10
mg/mL actinomycin D to block RNA polymerase activity. RNA
was extracted using RNeasy kits (Qiagen) from three biological
replicates at 0, 0.5, 2, 4, 8, and 16 h after treatment. For Znfx1 and
Zfas1, qPCR using random hexamers was used to quantify
expression relative to GAPDH. Snord12, Snord12b, and Snord12c
levels were determined from RNA isolated from 0, 2, 4, 8, and 16 h
after treatment and quantified as described in Supplemental
Methods. The control time point (t = 0) expression level was
set to 100% and treated samples shown as a percentage of the
control. A one-phase exponential decay curve and half-life value
were calculated using nonlinear regression with a least squares fit
by Prism 5 (plateau = unconstrained, k > 0). Where no decay was
present, a linear line was calculated using nonlinear regression
with a least squares fit.
RNA interference
Four pairs of siRNAs (see Supplemental Table S3) designed to
knockdown Zfas1 expression and one pair of scrambled siRNAs
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were purchased from Sigma. Equal quantities of HC11 cells (5 3
105) were seeded per well in 12-well plates, and the siRNA
knockdown was performed as described previously (Naylor
et al. 2005). Three replicates per time point were performed for
both the Znfx1/Zfas1 expression analysis (Fig. 3A) and b-casein
expression assay (Fig. 3E), and quantitative PCR was performed as
described above.
Proliferation assay
Quantification of cell proliferation based on the measurement of
BrdU incorporation during DNA synthesis was performed on cells
transfected with Zfas1 versus those transfected with scrambled
siRNA using the cell proliferation ELISA, BrdU colorimetric
immunoassay kit (Roche). Twenty-four hours after siRNA trans-
fection, cells were trypsinized, and six replicates of 12 3 103 cells
were seeded per well in a 96-well plate, with the no-cells well used
as a blank. Twenty-four hours after the cells were seeded in 96-
well plates, the cell proliferation assay was performed according to
the manufacturer’s instructions.
MTT assay
Twenty-four hours after HC11 transfection with Zfas1 versus
scrambled siRNA, cells were trypsinized, and six replicates of 123
103 cells were seeded per well in 96-well plates, with no-cells wells
used as blank. Proliferation was measured by an MTT (tetrazo-
lium blue) conversion test and tritiated thymidine uptake (Sigma
Aldrich). Briefly, 20 mL MTT (5 mg/mL) was added to each well
and the cells grown at 37°C for 4 h. After addition of 100 mL of
solubilization solution (10% SDS in 0.01 M HCl) cells were
incubated at 37°C for a further 3 h. Specific optical density of all
wells was then measured at 540 nm.
Dome formation assay
Twenty-four hours after HC11 transfection with scrambled versus
Zfas1 siRNA, cells were seeded in six-well plates. Assays for dome
formation were performed as documented previously (Naylor
et al. 2005). Briefly, cell differentiation was induced by the addition
of o-prolactin and dexamethasone. The number of domes in each
well was counted. Results presented here are from three experi-
ments with each individual assay performed in triplicate.
Statistical analyses
Two-tailed t-tests were performed for qPCR, proliferation, and
dome formation assays. Standard error of the mean was calculated
using Prism 5.0 (GraphPad Software, Inc.). Differential microarray
expression analysis was performed by the LIMMA package using
Bayesian statistics (B-statistics; posterior log odds) and Benjamini-
Hochberg multiple testing adjustment (see Supplemental Methods).
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